ReviewInternational journal of molecular sciences2026
Organoids-on-a-Chip: An Integrating New Technology for Drug Development.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Organoids-on-a-chip integrate the three-dimensional structural fidelity of organoids with the dynamic microenvironmental control capabilities of microfluidic technology, providing a transformative preclinical research platform for drug development. This perspective catalogues organoids-on-a-chip systems encompassing liver, heart, tumor, neural, tissue barrier, and multi-organ integration platforms, and elaborates on their distinctive advantages in dynamically simulating the complete in vivo trajectory of drug absorption, distribution, metabolism, target engagement, and toxicological response. The mechanisms of this technology overcome the limitations associated with conventional static culture models, and interspecies disparities are elucidated. Furthermore, the applications of these systems across critical stages of drug development are summarized, including preclinical safety assessment, integrated pharmacokinetic/pharmacodynamic studies, personalized therapeutics, immunotherapy evaluation, and disease molecular mechanisms. Finally, we highlighted the main challenges facing this field and discussed future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.